Please login to the form below
ThromboGenics
This page shows the latest ThromboGenics news and features for those working in and with pharma, biotech and healthcare.
NICE backs Novartis/ ThromboGenics’ eye drug
It is also good news for the drug's original developers ThromboGenics, which sold non-US rights for Jetrea to Novartis in 2012 in a deal worth up to 375m, and ... progressive disease much earlier and as soon as patients start experiencing symptoms
Latest news
-
NICE backs Novartis' Jetrea in rare eye condition
Once launched, Jetrea will be marketed by Novartis' eye division Alcon, which purchased non-US rights to the drug from Belgian pharma company ThromboGenics in March 2012. ... ThromboGenics retains the rights to commercialise the drug in the US, where it
-
Alcon wins initial NICE backing for Jetrea in rare eye condition
It purchased the rights to commercialise Jetrea outside the US from its developers ThromboGenics in 2012 as part of a deal potentially worth up to 375m.
-
Novartis, ThromboGenics' eye drug Jetrea gets green light in EU
The availability of the drug is a major boon for VMA patients, who until now have only had surgery as a treatment option, according to ThromboGenics. ... Jetrea was approved for symptomatic VMA last year in the US, where ThromboGenics has retained
-
Novartis' eye drug Jetrea recommended for EU approval
Novartis' Alcon division acquired commercialisation rights to Jetrea from its discoverer, the Belgium-based biopharmaceutical company ThromboGenics, in a 375m deal last March.
-
Amakem raises €18m for glaucoma treatment
Chris Buyse (Life Sciences Research Partners and CFO at Thrombogenics) who has been the company's chairman during its successful first phase will step down and Michael Palfreyman will take his
More from news
Approximately 3 fully matching, plus 6 partially matching documents found.
Latest appointments
-
ThromboGenics bolsters leadership team
Appoints Susan Schneider as CMO and Vinciane Vangeersdaele as CCO. ThromboGenics has strengthened its senior leadership team with the appointment of Susan Schneider, who joins the Belgian biotech as its chief ... Patrik De Haes, chief executive officer,
-
ThromoboGenics appoints Thomas Clay as chairman of the board
He moves from his previous position as non-executive director. Belgium-based biotech ThromboGenics has appointed non-executive director Thomas Clay as its new chairman of the board and succeeds Staf ... Clay has been a non-executive director of
More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Account Management
-
Competitive Salary Offered
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Senior Content Editor - Biotechnology
-
Salary TBC
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- AZ showcases data for next-generation PARP inhibitor AZD5305
- Sanofi pays $160m upfront to acquire Tidal Therapeutics
- GSK discontinues two feladilimab trials in head and neck cancer
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Pfizer/BioNTech say their COVID-19 vaccine can be stored at warmer temperatures
- FDA approves new self-injection administration for Xolair
- Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Alexion and NICE agree confidential discount for Ultomiris use on the NHS
- Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses
- Merck & Co halts development of potential COVID-19 drug MK-7110
- Virtually, the same: Is it time to rethink congress strategy?
PMHub
Health Unlimited
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...
Latest intelligence
- InSite Events™ National Pharma Meeting: A Customer Story
- How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
- Fear or encouragement, which is best to drive behaviour change?
- The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
- The unheard, unseen, and uncorrected effects of COVID-19
- The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...
Quick links
Infographics
